Success Metrics

Clinical Success Rate
92.6%

Based on 25 completed trials

Completion Rate
93%(25/27)
Active Trials
0(0%)
Results Posted
36%(9 trials)
Terminated
2(7%)

Phase Distribution

Ph phase_1
7
26%
Ph phase_3
15
56%
Ph phase_4
5
19%

Phase Distribution

7

Early Stage

0

Mid Stage

20

Late Stage

Phase Distribution27 total trials
Phase 1Safety & dosage
7(25.9%)
Phase 3Large-scale testing
15(55.6%)
Phase 4Post-market surveillance
5(18.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

92.6%

25 of 27 finished

Non-Completion Rate

7.4%

2 ended early

Currently Active

0

trials recruiting

Total Trials

27

all time

Status Distribution
Completed(25)
Terminated(2)

Detailed Status

Completed25
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
27
Active
0
Success Rate
92.6%
Most Advanced
Phase 4

Trials by Phase

Phase 17 (25.9%)
Phase 315 (55.6%)
Phase 45 (18.5%)

Trials by Status

terminated27%
completed2593%

Recent Activity

Clinical Trials (27)

Showing 20 of 27 trialsScroll for more
NCT03798080Phase 3

Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin

Completed
NCT03798054Phase 3

Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)

Completed
NCT03359837Phase 4

Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy

Completed
NCT03529123Phase 3

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)

Completed
NCT03434119Phase 3

Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents

Terminated
NCT03211858Phase 3

Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine

Completed
NCT03285594Phase 3

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents

Completed
NCT02713477Phase 1

Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus

Completed
NCT02752828Phase 3

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

Completed
NCT02273180Phase 3

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine

Completed
NCT02294474Phase 3

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine

Completed
NCT02058147Phase 3

Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM

Completed
NCT02058160Phase 3

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

Completed
NCT02200991Phase 4

Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine

Completed
NCT01234597Phase 4

Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day

Completed
NCT01689142Phase 3

Comparison of a New Formulation of Insulin Glargine With Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus

Completed
NCT01223131Phase 3

Efficacy and Safety of Insulin Glargine Versus. Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Above 6 Years Old.

Completed
NCT01676233Phase 1

Repeated Dose Study With a New Insulin Glargine Formulation and Lantus® on 24-hour Glucose Profile in Japanese Patients With Type 1 Diabetes Mellitus

Completed
NCT00069784Phase 3

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)

Completed
NCT00965549Phase 4

Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients

Completed

Drug Details

Intervention Type
DRUG
Total Trials
27